Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (June 2021)
33 slides from Eyepoint's investor presentation, Jun 2, 2021
Slide 1: Delivering Innovation to the Eye – Investor Presentation June 2021
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation June 2021 Exhibit 99.1
Slide 2: Forward-looking statements
Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but n
Slide 3: Company Overview: Proven technology driving pipeline growth
COMPANY OVERVIEW Proven technology driving pipeline growth 3 | EYEPOINT PHARMACEUTICALS Compelling pipeline focused on retinal disease EYP-1901 - potential twice yearly treatment for wet AMD, diabetic retinopathy and retinal vein occlusion YUTIQ50 – potential twice yearly treatment for posterior uve
Slide 4: Durasert Platform: Proven sustained release intraocular drug delivery
5 | EYEPOINT PHARMACEUTICALS DURASERT® Platform Proven sustained release intraocular drug delivery TECHNOLOGY 4 | EYEPOINT PHARMACEUTICALS
Slide 5: Durasert: Proven sustained release delivery
TECHNOLOGY DURASERT® Proven sustained release delivery Four FDA-approved products with multiple programs in development Single intravitreal injection Continuous, stable release to the back of the eye provides consistent and reliable drug delivery over weeks, months or years Simple administration in
Slide 6: Pipeline: Building on a Proven Platform
PIPELINE Building on a Proven Platform 6 | EYEPOINT PHARMACEUTICALS
Slide 7: Retinal disease focused pipeline
17 | EYEPOINT PHARMACEUTICALS Retinal disease focused pipeline
Slide 8: EYP-1901 - Potential Twice a Year Anti-VEGF Treatment
EYP-1901 - Potential Twice a Year Anti-VEGF Treatment 8 | EYEPOINT PHARMACEUTICALS PIPELINE Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion
Slide 9: EYP-1901 Opportunity to transform the treatment of wet AMD
VEG PIPELINE EYP-1901 Opportunity to transform the treatment of wet AMD The need... Currently, wet AMD patients often lose vision despite anti-VEGF therapy due to undertreatment The EYP-1901 solution... Potential twice yearly in-office injection of anti-VEGF therapy Anti-VEGF therapy (vorolanib) del
Slide 10: Real world need: today's wet AMD treatments still result in vision loss
PIPELINE EYP-1901 Real world need... today's wet AMD treatments still result in vision loss over time RETROSPECTIVE, OBSERVATIONAL STUDY IN 2,227 PATIENTS WITH WET AMD Mean Visual Difference From Baseline (LOCF)(Letters) 6 Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela To
Slide 11: Real world data from the U.S.
...including real world data from the U.S. PIPELINE EYP-1901 Adjusted Mean Change From Baseline in VA Letter Score 3 6 12 Month 12 p=0.67† Aflibercept Ranibizumab 1.52 1.01 -0.19 1.24 0.71 -0.30 Follow-up (Month) Lotery et al., Eye (2017) 31, 1697–1706 RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 430
Slide 12: EYP-1901: Intravitreal delivery of vorolanib using bioerodible Durasert
EYP-1901 Intravitreal delivery of vorolanib using a bioerodible formulation of Durasert® Vorolanib Tyrosine kinase inhibitor (TKI) studied as an oral therapy for wet AMD through Phase 2 with strong clinical signal and no significant ocular adverse events Blocks all 3 isoforms of VEGFR, the main driv
Slide 13: Effective blocking of VEGFR prevents neovascularization and loss of vision
23 | EYEPOINT PHARMACEUTICALS Effective blocking of VEGFR prevents neovascularization and loss of vision PIPELINE EYP-1901 VEGF-B VEGF-C VEGF-D VEGF-A R1 / INFLAMMATION R2 / BLOOD VESSEL LEAKAGE R3 / BLOOD VESSEL GROWTH & LEAKAGE VEGF SIGNALING PATHWAYS VOROLANIB VOROLANIB VOROLANIB 13 | EYEPOINT PH
Slide 14: A potent inhibitor of VEGFR
A potent inhibitor of VEGFR Vorolanib blocks VEGFR2 at the same level as sunitinib, a proven anti-VEGF therapy The inhibitor constant (Ki) of sunitinib for VEGFR is reported to be low (5 ng/mL), an indication of strong inhibition. Since Ki is related to IC50, similar inhibition Ki is expected for vo
Slide 15: EYP-1901 pre-clinical results
6-month rabbit GLP toxicology completed with no unexpected safety findings Efficacy and preliminary safety study completed in a laser CNV mini pig model Results: dose-related activity and no observed toxicity Non-GLP rabbit PK and safety study demonstrated drug levels in vitreous and retina/choroid
Slide 16: EYP-1901 in-vitro release of vorolanib in a single insert
EYP-1901 in-vitro release of vorolanib in a single insert PIPELINE EYP-1901 16 | EYEPOINT PHARMACEUTICALS Zero order release through ~8 months followed by new zero order rate through at least 12 months
Slide 17: In-vivo release of vorolanib in rabbits measured over ~8 months
In-vivo release of vorolanib in rabbits measured over ~8 months PIPELINE EYP-1901 17 | EYEPOINT PHARMACEUTICALS Linear decrease in residual drug in inserts indicates zero order drug release
Slide 18: In-vivo cumulative % release of vorolanib in rabbits
In-vivo cumulative % release of vorolanib in rabbits measured over ~8 months PIPELINE EYP-1901 18 | EYEPOINT PHARMACEUTICALS R2 for both doses indicates zero order release of drug at different dosing levels
Slide 19: Oral vorolanib clinical results – Phase 1
Oral vorolanib clinical results – Phase 1 Demonstrated clinical activity in wet AMD Phase 1 trial design Open label, 24 weeks, dose escalation, no control, oral delivery; 80% of eyes enrolled previously treated; 4 eyes treatment naïve N=35; 25 completers Phase 1 results BCVA was maintained to within
Slide 20: Oral vorolanib clinical activity in wet AMD Phase 2 trial
Oral vorolanib clinical activity in wet AMD Phase 2 trial Less rescue vs placebo for all doses with no ocular toxicity PIPELINE EYP-1901 Strict pre-defined rescue criteria with anti-VEGF therapy Any increase in fluid on OCT compared to screening visit 2 (~14 days after an IVT injection) New or incre
Slide 21: EYP-1901 Phase 1 Trial
EYP-1901 Phase 1 Trial 21 | EYEPOINT PHARMACEUTICALS
Slide 22: Phase 1 DAVIO wet AMD clinical trial design
29 | EYEPOINT PHARMACEUTICALS 1-2 weeks following last injection RESULTS ENROLLMENT DOSE A DOSE B DOSE C Open label, dose escalation, no control arm (results to be monitored on an ongoing basis) Rescue with anti-VEGF therapy if necessary 6 month readout Patients with wet AMD responsive to previous a
Slide 23: DAVIO wet AMD clinical trial underway with enrollment completed in May 2021
Phase 1 DAVIO wet AMD clinical trial underway with enrollment completed in May 2021 PIPELINE EYP-1901 1H 2021 2H 2021 PHASE 1 TRIAL PRELIMINARY RESULTS EXPECTED IN Q4 2021 FIRST PATIENT DOSED 23 | EYEPOINT PHARMACEUTICALS UPDATE Enrollment completion announced May 25, 2021 17 patients in total dosed
Slide 24: Products: FDA Approved Commercial Products
PRODUCTS FDA Approved Commercial Products 24 | EYEPOINT PHARMACEUTICALS
Slide 25: YUTIQ: Continuous calm in uveitis
Approved for the treatment of chronic non-infectious uveitis affecting the back of the eye Commercially launched in U.S. in 2019 Patent protection to August 2027 Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years LICENSE AGREEMENTS Alimera Scienc
Slide 26: Chronic non-infectious uveitis causes blindness with every flare
PRODUCTS 60K–100K patients are suffering from uveitis in the U.S. The need Flares can cause blindness 30,000 Americans become blind each year because of uveitis Uveitis lasts a lifetime and often affects people in middle age The YUTIQ answer 3-year continuous treatment in a single injection that con
Slide 27: Continuous 3-year delivery limits uveitis flares
PRODUCTS CONTINUOUS CALM IN UVEITIS Continuous 3-year delivery limits blindness-causing uveitis flares Time to recurrence of uveitis within 36 months YUTIQ MEDIAN TIME TO FIRST RECURRENCE: 1051 DAYS PROBABILITY RECURRENCE 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 60 120 180 240 300 360 420 480 5
Slide 28: Customer demand returning from COVID shutdowns
28 | EYEPOINT PHARMACEUTICALS PRODUCTS Customer demand returning from COVID shutdowns COVID-19 Shutdown CUSTOMER DEMAND IN UNITS CONTINUOUS CALM IN UVEITIS
Slide 29: DEXYCU: Target the site
Treatment of inflammation following ocular surgery Single long-lasting injectable treatment compared to low compliance eyedrop regimen Effective in preventing inflammation after cataract surgery with proven safety record Co-promoted with ImprimisRX, an established commercial organization in the cata
Slide 30: The U.S. cataract surgery market is large and growing
PRODUCTS The U.S. cataract surgery market is large and growing 3.8 million cataract surgeries in 2018 The need As the baby boom generation ages, cataract surgery will become even more common The DEXYCU answer Today, eyedrops are the most common treatment after cataract surgery Patients forget to tak
Slide 31: Customer demand returning from COVID shutdowns
28 | EYEPOINT PHARMACEUTICALS PRODUCTS Customer demand returning from COVID shutdowns TARGET THE SITE COVID-19 Shutdown CUSTOMER DEMAND IN UNITS
Slide 32: Financial Summary
DELIVERING INNOVATION TO THE EYE Financial Summary $138.5 million of Cash on March 31, 2021, funds operations through Q4 2022 $6.8 million net product revenues in Q1 2021, a 45% increase over Q1 2020 2020 total revenues of $34.4 million, including $20.8 million of net product revenue 2019 Total reve
Slide 33: Delivering Innovation to the Eye
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye
EyePoint Pharmaceuticals — Investor Presentation (June 2021) on 6ix